This is a summary of the European public assessment report (EPAR) for Clopidogrel BGR. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel BGR.
Therapeutic Indication
### Therapeutic indication Prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
Therapeutic Area (MeSH)
ATC Code
B01AC03
ATC Item
picotamide
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| clopidogrel (as hydrogen sulfate) | N/A | clopidogrel (as hydrogen sulfate) |
EMA Name
Clopidogrel BGR (previously Zylagren)
Medicine Name
Clopidogrel BGR (previously Zylagren)
Aliases
N/ANo risk management plan link.
